MariMed (OTCMKTS:MRMD – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports. MariMed had a negative net margin of 9.27% and a negative return on equity of 12.73%. The firm had revenue of $44.23 million for the quarter, compared to analyst estimates of $41.20 million.
MariMed Stock Performance
Shares of MRMD opened at $0.07 on Friday. The stock has a 50-day moving average of $0.07 and a two-hundred day moving average of $0.07. MariMed has a one year low of $0.04 and a one year high of $0.16. The company has a quick ratio of 0.34, a current ratio of 0.92 and a debt-to-equity ratio of 1.78.
About MariMed
MariMed, Inc. is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products. MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.
Read More
- Five stocks we like better than MariMed
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
